Orient: Initiates a "Buy" rating for Hutchmed (China) (00013) with a Target Price of 33.24 HKD.
Orient predicts that Hutchmed (China) (00013) will have revenue of 680 million, 844 million, and 1 billion dollars for the years 2024-2026 respectively.
Daiwa Securities Initiates Coverage on HUTCHMED With Buy Rating, $23 Price Target
Hutchmed to Receive $10 Million Milestone Payment Through Takeda
Express News | Reported Earlier, HUTCHMED to Receive $10M Payment From Takeda As FRUZAQLA Achieves First National Reimbursement In Europe For Metastatic Colorectal Cance
Hutchmed (China) (00013.HK): Following the first inclusion of FRUZAQLA (fruquintinib) in the healthcare insurance in Europe, a milestone payment from Takeda will be received.
Gelonghui reports on December 13 that Hutchmed (China) (00013.HK) announced it will receive a $10 million milestone payment from its partner Takeda (TSE: 4502/NYSE: TAK). Takeda has received a recommendation in December 2024 for FRUZAQLA to be included in public medical coverage for patients with previously treated metastatic colorectal cancer in Spain, marking the first recommendation for public medical coverage obtained in Europe. Colorectal cancer is the second leading cause of cancer-related deaths in Europe. FRUZAQLA received approval from the European Commission in June 2024.
Reported Earlier, HUTCHMED's ORPATHYS and TAGRISSO Combo Gains Therapy Designation in China for Advanced Lung Cancer
